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Renoprotection: One or many therapies? The term “renoprotection” often evokes a single image:
Background. Renal disease that progresses to end-stage re- angiotensin-converting enzyme (ACE) inhibition therapy
nal disease (ESRD) imposes a great burden on the affected to slow the “progression of renal disease.” ACE inhibi-
individual and on society, which mainly bears the cost of ESRD
tors certainly deserve that reputation [1]. Nevertheless,(currently more than $10 billion to treat about 333,000 patients
this therapy alone rarely stops renal disease progression.annually in the U.S.). Thus, there is a great need to identify
Herein, we describe a multiple-risk-factor interventiontherapies that arrest the progression mechanisms common to
all forms of renal disease. Progress is being made. Perhaps the strategy based on inhibiting the progression mechanisms
most visible advance is the randomized controlled trials (RCT) believed to be common to most forms of progressive
demonstrating the renoprotective effects of angiotensin-con- renal disease. To assist the treating physician, each inter-
verting enzyme (ACE) inhibitors. There are also numerous
vention is described in substantial practical detail andother promising renoprotective therapies. Unfortunately, test-
prioritized according to level of recommendation. Theing each therapy in RCT is not feasible. Thus the nephrologist
incentive to use the multiple-risk-factor intervention ishas two choices: restrict renoprotective therapy to those shown
to be effective in RCT, or expand the use of renoprotective that each intervention is either of proven value or plausi-
therapies to include those that, although unproven, are plausi- bly effective and prudent to use. Furthermore, renal dis-
bly effective and prudent to use. The goal of this work is ease generally progresses slowly [glomerular filtration
to provide the documentation needed for the nephrologist to
rate (GFR) loss of about 3 mL/min/year] [2]. Thus, evenchoose between these strategies.
small improvements in slowing renal disease progressionMethods. This work first describes the mechanisms believed
can provide large benefits (Fig. 1). Our hypothesis is thatto be involved in the progression of renal disease. Based largely
on this information, 18 separate interventions that slow the the benefit of the multiple-risk-factor intervention is the
progression are described. Each intervention is assigned a level summation of multiple small beneficial effects.
of recommendation (Level 1 is the highest and Level 3 the In the present context, “progression of renal disease”
lowest) according to the strength of evidence supporting its
refers to an irreversible decline in GFR because of struc-renoprotective efficacy.
tural damage to the renal vasculature, tubules or intersti-Results. The number of interventions at each level of recom-
tium. In most studies of progression of renal disease,mendation are: Level 1, N 5 4; Level 2, N 5 4; Level 3, N 5 10.
Our own experience with the multiple-risk-factor intervention histologic documentation of structural damage was not
is that most patients can achieve the majority of the Level 1 demonstrated by renal biopsy. Rather, it was assumed
and 2 interventions, and many of the Level 3 interventions. because the loss of GFR was irreversible.
We recommend the expanded renoprotection strategy.
The renoprotective strategies proposed are based onConclusion. This work advances the hypothesis that, until
clinical and experimental studies that have examined thebetter information becomes available, a broad-based, multiple-
mechanisms of renal disease progression. The interac-risk-factor intervention intended to slow the progression of
renal disease can be justified in those with progressive nephrop- tions of these mechanisms with each other are probably
athies. This work is intended primarily for clinical nephrologists exceedingly complex. To illustrate this point consider
and thus each recommended intervention is described in sub- Figure 2. This paradigm explains how blood pressure
stantial practical detail.
control might slow the progression of renal disease
through its effect to decrease proteinuria. This paradigm
would become far more complex if it included the otherKey words: angiotensin II, progressive renal disease, ACE inhibitors,
relevant mechanisms of renal disease progression.multiple-risk-factor intervention, glomerular filtration rate, hyperten-
sion. A further reason to eschew a comprehensive paradigm
is that we do not have a clear idea of how the variousReceived for publication January 6, 2000
renoprotective mechanisms interact. For example, theand in revised form October 6, 2000
Accepted for publication October 11, 2000 optimal use of ACE inhibitors (ACE I) for renoprotec-
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Fig. 1. Rate of glomerular filtration rate (GFR) decline in normals and
in hypothetical patients with onset of progressive renal disease at age
25. The course of GFR decline with normal aging (top curve) is based
on a cross-sectional study of iothalamate clearance in 357 patients aged
17 to 70 years [7]. Note that a GFR loss of greater than 1 mL/min/year
beginning at age 25 can result in end-stage renal disease within a normal
lifespan. Note also that small differences in rates of GFR decline can Fig. 2. Possible interactions of hypertension, proteinuria, and glomeru-
result in large differences in time to onset of end-stage renal disease. lar filtration rate (GFR) loss in patients with glomerulopathy. The
interactions are shown as numbered arrows. It is proposed that arrows
1 through 4 represent primary effects of the interactions. The relative
importance of these primary and secondary effects is unknown (re-
printed from Hebert et al, with permission of the International Societycause blood pressure control in those trials was not opti-
of Nephrology) [11].mal. Specifically, the Modification of Diet in Renal
Disease (MDRD) Study (which was published after the
ACE I studies were begun) showed that in proteinuric
renal disease, systolic blood pressures in the low generally spared, unless the hypertension is severe. Thus,120s mm Hg slowed the progression of renal disease
proteinuria is usually minimal in progressive hyperten-better than systolic blood pressures in the low 130s
sive arteriolar nephrosclerosis, a condition rarely seenmm Hg [2]. In contrast, in the randomized trials that
in Caucasians but often seen in African Americans [8].tested ACE I renoprotection (the MDRD Study used
Hypertension-induced tissue injury may involve stretch-ACE I but not as randomized intervention), the mean
induced tissue fibrosis [9] and up-regulation of intercellu-achieved systolic blood pressure was typically in the 140s
lar adhesion molecules, which results in renal infiltrationmm Hg [3, 4]. Also, the randomized trials used only low
of lymphocytes and macrophages [10]. When hyperten-to moderate doses of ACE I [5]. Thus, the optimum
sion is superimposed on intrinsic renal disease, the re-renoprotective ACE I dose and blood pressure level
sulting arteriolar nephrosclerosis adds to renal diseasehave not been clarified by the randomized trials [6].
progression. In proteinuric renal disease, hypertensionIn light of the uncertainty of how renoprotective mech-
anisms interact when they are deployed simultaneously, creates a vicious cycle promoting progression of renal
later in this article, we simply list the mechanisms and disease (Fig. 1) [11]. This cycle is particularly adverse in
interventions, both the proven and plausible, and their African Americans [8].
possible modes of action. Patients with autosomal poly-
cystic kidney disease (ADPKD) merit special considera- Proteinuria
tions with respect to progression mechanisms and thera- Nonselective proteinuria contains numerous toxic/
peutic interventions. These are discussed in relationship inflammatory systems that promote the progression of
to each of the relevant mechanisms or therapies. The renal disease [reviewed in 12, 13]. The best studied toxic/
mechanisms of renal disease progression are discussed inflammatory systems are complement, inflammatory li-
first, followed by the recommended interventions, which
poproteins, iron species, and protein overload of proxi-are ranked according to the level of recommendation.
mal tubular epithelial cells. All components of the alter-
native complement pathway are present in nonselective
MECHANISMS OF RENAL proteinuria. Membrane attack complex (MAC; C5b-9)
DISEASE PROGRESSION is deposited on proximal tubular epithelium [14] causing
Hypertension tubular and interstitial injury [15, 16]. Inflammatory lipo-
proteins interact with renal tubular epithelial cells induc-Increased blood pressure may impair kidney function
by inducing arteriolar nephrosclerosis [7]. Glomeruli are ing chemokines, which promote inflammation. Filtered
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serum iron or transferrin induces free oxygen radical plain the adverse effects of increased protein intake on
renal disease progression.formation, which is toxic to renal tubular epithelial cells.
An overload of the protein transport systems of proximal
Increased NaCl intaketubular epithelial cells leads to induction of chemokines
In the MDRD Study, baseline urinary sodium excre-[17], nitric oxide (NO) [18], and growth factors such as
tion (reflecting NaCl intake) was not an independenttransforming growth factor-b (TGF-b) [19].
risk factor for the progression of renal disease [31]. Nev-These toxic/inflammatory compounds probably induce
ertheless, high salt intake can override the antiprotein-(1) glomerular injury mainly to podocytes promoting
uric effect of ACE I and calcium channel blocker therapyproteinuria [20]; (2) tubular injury from C5b-9 deposi-
[32, 33], and this could promote renal disease progres-tion, inflammatory cell infiltration (induced by chemo-
sion.kines), and free radical formation (induced by Fe31); and
(3) tubular epithelial hyperplasia from growth factors
Increased fluid intakeand mitogens induced by proteinuria through comple-
Analysis of the MDRD database showed that higherment [21, 22] and by filtered insulin-like growth factor-
follow-up mean 24-hour urine volume and lower mean1 (IGF-1) [23]. These are apparently responsible for the
24-hour urine osmolality during follow-up were associ-proximal tubular epithelial cell hyperplasia that en-
ated with more rapid GFR decline, particularly incroaches on tubular lumen in proteinuric renal disease
ADPKD patients (abstract; Hebert et al, J Am Soc[13]. Finally, these compounds induce tubulointerstitial
Nephrol 11:148A, 2000). The high urine volumes werefibrosis by proteinuria-induced TGF-b and endothelin-1
associated with maintained or increased blood pressure(ET-1) [reviewed in 17].
and greater diuretic use. Thus, the high urine volumes
were not explained by more aggressive renal diseaseExcess angiotensin II
causing a renal concentrating and salt-wasting defect andAngiotensin II (Ang II) may promote renal disease
polyuria. If chronically high urine volume promotes pro-progression by inducing glomerular hypertension, glo-
gression of renal disease, the effect may be due to adversemerular hypertrophy, mitogens such as platelet-derived
effects of increased intratubular pressure caused by highgrowth factor (PDGF), fibrosis through TGF-b or ET-1,
urine volume.ammonia formation leading to activation of the alterna-
tive complement pathway, inflammatory intracellular sig- Hyperlipidemia
naling mechanisms, including nuclear transcription factor
Elevated plasma lipids adversely influence the pro-
kB (NF-kB), increased tubular absorption of sodium and
gression of experimental nephropathy [34]. There have
oxygen consumption, increased oxidant stress, and in- been no definitive controlled clinical trials in patients
creased aldosterone leading to increased blood pressure that demonstrate a benefit from lipid control on the
and tissue fibrosis [reviewed in 1, 12, 24]. Ang II also progression of renal disease [34]. Hyperlipidemia could
increases expression of monocyte chemoattractant pro- adversely affect glomerular function because of the up-
tein-1 (MCP-1), a potent chemokine [25, 26] that can take of oxidized lipoproteins [34]. Hyperlipidemia can
induce inflammation and fibrosis through TGF-b [25]. also lead to atherosclerosis of the renal arteries and its
Ang II increases plasminogen activator inhibitor-1 (PAI-1) major branches, particularly in the older population (un-
favoring thrombosis and progressive sclerosis [27]. published observations).
Hyperglycemia Cigarette smoking
Elevated blood glucose causes glomerular hyperfiltra- Smoking has vasoconstrictor, thrombotic, and direct
tion, hypertrophy, and hypertension. High glucose in- toxic effects on the vascular endothelium. Cigarette
duces renal matrix proteins, which accumulate and inter- smoking is an independent risk factor for progression of
fere with vascular function. These can occur with even inflammatory renal disease (IgA nephritis), noninflam-
mild hyperglycemia if it is of sufficient duration and with matory renal disease (ADPKD), and diabetic nephropa-
appropriate genetic risk factors [28]. thy [reviewed in 35].
Increased protein intake Increased plasma homocysteine
Protein ingestion acutely increases GFR and protein- Hyperhomocystinemia develops as GFR declines (ab-
uria apparently by increased renin and eicosanoids and stract; Falkenhain et al, J Am Soc Nephrol 10:163A, 1999)
effects of individual amino acids [29], including NO pro- [36] apparently as a result of changes in renal metabolism
duction by l-arginine [30]. These effects persist if the rather than decreased urinary excretion [36]. Hyperho-
increased protein intake is sustained [2]. Thus, glomeru- mocystinemia is a risk factor for atherothrombosis [37]
and microalbuminuria in diabetic nephropathy [38], pos-lar hyperperfusion and increased proteinuria may ex-
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sibly because of endothelial injury by oxidant stress. A Increased levels of procoagulants
recent study did not find a significant correlation between Above-average levels of fibrinogen, factor VIII, and von
plasma homocysteine and progression of renal disease Willebrand factor were independently related to increased
[39]. This is not surprising given the small size of the study. serum creatinine during follow-up of the 12,208 patients
in the Atherosclerosis Risk in Community (ARIC) Study
Increased endogenous insulin (increased C-peptide) (abstract; Coresh et al, J Am Soc Nephrol 10:606A, 1999).
Insulin resistance is a cardiovascular risk factor in hu-
Gendermans [40]. In experimental models of insulin resistance,
high plasma insulin levels (and/or triglycerides) induce Renal diseases usually have a higher prevalence and
glomerular sclerosis [41] perhaps because insulin induces more rapid progression in men than women [49]. The
fibrosis and glomerular hyperperfusion [40]. These ef- postulated mechanisms include estrogen’s favorable ef-
fects might explain the association of microalbuminuria fects on glomerular hemodynamics, blood lipids, cyto-
with insulin resistance in nonobese subjects and the in- kines that promote progression via mitogenic growth,
creased incidence of focal and segmental glomeruloscle- and fibrosis [49]. Estrogen therapy raises blood pressure.
rosis (FSG) in obese individuals and African Americans Nevertheless, women have lower blood pressure than
men [49]. Estrogens antagonize the effects of aldoste-[42], both of whom often manifest insulin resistance.
rone, which could lessen the postulated fibrogenic effect
Nonsteroidal anti-inflammatory agents of aldosterone [24].
Nonsteroidal anti-inflammatory agents (NSAIDs) cause
acute and usually reversible decreases in GFR, and idio- A MULTIPLE-RISK-FACTOR INTERVENTION
syncratic forms of membranous nephropathy and inter- STRATEGY TO SLOW THE PROGRESSION OF
stitial nephritis, both associated with nephrotic syndrome RENAL DISEASE
[43]. The literature is less clear as to whether chronic
The strategy for the multiple-risk-factor interventiondaily use of NSAIDs causes progressive nephrotoxicity
is based on the proven and the plausible mechanisms of[43]. However, our clinical experience strongly suggests
progression of renal disease, as discussed previously inthat it does (unpublished observations).
this article. The therapeutic interventions we recom-
mend are listed in Table 1 according to the level ofHyperphosphatemia
recommendation. Level 1 (highest) recommendations
Animal models and human studies indicate that hyper-
are based on the primary analysis of one or more large
phosphatemia promotes progression of renal disease, clinical trials that are prospective, randomized, and con-
perhaps by causing renal calcium and phosphorus depo- trolled. Level 2 (intermediate) recommendations are
sition and/or hyperparathyroidism [44]. based on a secondary analysis of one or more of the
trials that provided Level 1 recommendations, high-qual-Anemia
ity case control studies, or randomized controlled trials
A small-randomized trial in patients suggested that if that involved relatively small numbers of patients. The
blood pressure is controlled, renal disease progression Level 3 (lowest) recommendations are based on observa-
is slowed by correction of the anemia with erythropoietin tional studies or studies in experimental renal disease.
[45]. The possible mechanism is unclear; however, glo- Each renoprotective intervention is discussed in more
merular damage impairs renal blood flow and may cause detail in the following paragraphs.
renal hypoxia, which is a fibrogenic stimulus [46].
1. Control blood pressure (Level 1)
Excess aldosterone The belief that blood pressure control is important in
Mineralocorticoids appear to induce myocardial and slowing progression of renal disease has been strongly
renal fibrosis, perhaps through increased expression of held for decades; however, this belief was not confirmed
plasminogen activator-1 (PAI-1) [24]. until 1994 when the MDRD Study published its results
of its randomized intervention study [2]. The key findings
Potassium depletion and our recommendations based on those findings are
Sustained potassium depletion can be associated with as follows:
progressive renal interstitial fibrosis [47]. The mechanism In those with proteinuria .1 g/24 hours, the low
may be induction of growth factors and matrix produc- blood pressure goal (mean achieved blood pressure
tion factors, including those in the TGF-b family. Potas- ,125/75 mm Hg) slowed progression of renal disease
sium depletion in experimental animals also induces re- better than the usual blood pressure goal (mean achieved
nal hypertrophy, apparently through induction of growth blood pressure ,135/85 mm Hg).
The greater the proteinuria, the greater was the benefitfactors [48].
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Table 1. Renoprotective strategies ranked according to level of recommendation
Intervention Goal/comments
1. Control blood pressure (Level 1) Sitting systolic blood pressure in the 120s or lower, if tolerated. This goal is recommended
for all patients with progressive renal disease but it is particularly important if proteinuria
.3.0 g/24 hours. Text has recommended antihypertensive regimens.
2. ACE inhibitor therapy (Level 1) Use ACE I even if normotensive.
Angiotensin receptor blocker (ARB) if Renoprotection has been demonstrated with low- to moderate-dose ACE I therapy. Opti-
ACE inhibitor intolerant (Level 3) mum dose is unknown.
If proteinuric, goal is to reduce proteinuria to ,1.0 g/24 hours. ACE I should be used
primarily to achieve the proteinuria goal. ACE I generally are not potent antihypertensive
agents in chronic renal insufficiency. Thus escalation of the ACE I dose should not be
the primary means to achieve the blood pressure goal.
3. Control blood glucose in diabetics (Level 1) In type 1 diabetics, goal is hemoglobin A1C (Hgb A1C) within 2 percentage points of the
upper limits of normal of the given assay.
In type 2 diabetics, goal is normal Hgb A1C.
4. Dietary interventions Goal is 0.7 to 0.8 g/kg ideal body weight/day. To achieve goal, may need to instruct @ 0.6
Protein intake (Level 1) g/kg ideal body weight/day.
NaCl intake (Level 3) NaCl 80 to 120 mmol/24 hours (,2.0 to 3.0 g Na intake) to optimize the antiproteinuric
effect of ACE I, ARB or CCB therapy. NaCl restriction does not apply if renal salt
wasting is present. NaHCO3 therapy does not count towards dietary NaCl goal.
Fluid intake (Level 2) A high fluid intake that results in a 24-hour urine volume exceeding 2.0 L/24 hours is not
beneficial and might be associated with more rapid GFR decline. This recommendation
does not apply if nephrogenic or hypothalamic diabetes insipidus is present. ADPKD
patients may particularly benefit from avoidance of a high fluid intake.
5. Control blood lipids (Level 1 for cardiovascu- LDL cholesterol ,120 mg/dL (,100 mL/dL may be even better especially if atherosclerosis
lar benefit, Level 2 for renal benefit) is present or suspected). HMG CoA reductase inhibitor therapy, which lowers LDL
cholesterol may also have anti-inflammatory effects that are renoprotective.
6. No cigarette smoking (Level 1 for general No cigarette smoking.
benefit, Level 2 for renal benefit)
7. Avoid regular use of NSAIDs (Level 3 based NSAIDs once or twice weekly (e.g., for headaches) seems safe. See text for discussion of
on published evidence, Level 1 based on alternatives to NSAIDs.
clinical experience)
8. Control plasma homocysteine (Level 2 for Use folic acid (2 to 15 mg daily) to reduce total plasma homocysteine to normal. May be
cardiovascular benefit, Level 3 for renal difficult in advanced renal insufficiency. Blood vitamin B12 levels must be normal. Vitamin
benefit) B6 and B12 supplement may be necessary.
9. Control hyperinsulinemia (Level 2 for cardio- Lose excess weight, exercise, hyperinsulinemia (elevated C-peptide) is a strong cardiovascu-
vascular benefit, Level 3 for renal benefit) lar risk factor and may promote glomerulosclerosis.
10. Use antioxidants (Level 3) Vitamin C 200 mg daily is recommended. Vitamin E might also be useful.
11. Correct anemia (Level 1 for general benefit, Hemoglobin 11 to 12 g/dL is recommended. Erythropoietin therapy is usually necessary.
Level 2 for renal benefit)
12. Avoid hypokalemia (Level 1 for general May be especially important to avoid hypokalemia in ADPKD to prevent cyst growth.
benefit, Level 3 for renal benefit)
13. Control hyperphosphatemia (Level 1 for The goal is normal serum phosphorus level. Dietary phosphorus restriction and phosphorus
general benefit, Level 3 for renal benefit) binder may be needed.
14. Low dose aspirin therapy (Level 1 for general The goal is to attenuate the effects of increased procoagulants to promote progression of
benefit, Level 3 for renal benefit) renal disease. Aspirin, 81 mg daily, is recommended. Do not use if blood pressure is
not controlled or if renal bleeding occurs. Addition of dipyridamole therapy may provide
further benefit.
15. Estrogen replacement therapy in women The goal is the usual level of estrogen replacement in post-menopausal women with renal
(Level 2 for general benefit, Level 3 for disease for whom no contraindications for estrogen therapy are present. Estrogen effects
renal benefit) may explain the slower progression of renal disease in women compared to men.
See text for definition of level of recommendation and further detail regarding each intervention, as well as for a description of the patients for whom these
interventions are recommended. Abbreviations are in the Appendix.
of achieving the low blood pressure goal. Those with cline (,7 to 14 mL/min/year). These patients derived
great benefit from assignment to the low blood pressureminor proteinuria (,1 g/24 hours) generally had slow
rates of GFR decline (,3 to 4 mL/min/year), and this goal whose GFR decline was approximately 7 mL/min/
year compared with approximately 13 mL/min/year forrate of GFR decline was affected little by the low blood
pressure goal over the 2.2 years of follow-up in the those assigned to the usual blood pressure goal. Protein-
uric African Americans especially benefited by achievingMDRD Study. In contrast, those with heavy proteinuria
(.3.0 g/24 hours) generally had rapid rates of GFR de- the low blood pressure goal [8].
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eases. Thus, it is possible that some patients may not
tolerate the low blood pressure goal.
The fall in GFR of ADPKD patients in the MDRD
study was not slowed by the low blood pressure goal [51].
However, the low blood pressure may slow ADPKD
progression if therapy is begun before 50% of GFR is
lost [52].
Method for assessing blood pressure control
Blood pressure is taken in the sitting position and after
the patient has taken that morning’s antihypertensive
medication. If the patient’s office blood pressure is not
at goal, home blood pressure monitoring using calibrated
equipment and proper technique is recommended. If
home blood pressure is accurately measured, we recom-
mend that it be taken as the extent to which the patient
is achieving his/her blood pressure goal [53].
Recommended antihypertensive regimens
Nonpharmacologic therapy of hypertension. Restrict
salt intake (Table 1, and later in this article). Lose excess
weight. Avoid more than two drinks of alcohol per day
as well as vasoconstrictor nose drops or eye drops, de-
congestants, amphetamines, anabolic steroids, high-dose
estrogen therapy, cocaine, amphetamines, and yohim-Fig. 3. Changes in urine protein from baseline to selected follow-up
times in study A. This is a comparison of changes from baseline in bine [7].
urine protein between patients in the usual (dotted line) and the low Initial pharmacologic therapy of hypertension. The se-
(solid line) blood pressure groups within subgroups defined according
quence shown here is that recommended until the patientto baseline proteinuria. Proteinuria was log transformed. Changes in
proteinuria are expressed as percentage changes. Three hundred five reaches his or her blood pressure goal: (1) low-dose
patients had baseline proteinuria of 0 to 0.25 g/day (mean 0.08 g/day). ACE I therapy (starting dose recommended by manufac-
One hundred twenty had baseline proteinuria of 1.0 to 3.0 g/day (mean
turer) plus dietary salt restriction (Table 1); (2) moder-1.8 g/day), and 55 had baseline proteinuria of 3.0 g/d or more (mean,
4.8 g/day; reprinted with permission from Peterson et al, Annals of ate-dose ACE I therapy (2 to 4 times the recommended
Internal Medicine) [50]. starting dose) plus dietary salt restriction; or (3) moder-
ate-dose ACE I therapy plus dietary salt restriction plus
diuretic therapy. Furosemide is the recommended di-
uretic because it is more effective than thiazide diureticsAchieved systolic blood pressure predicted GFR de-
in impaired kidney function and is less expensive thancline better than achieved diastolic blood pressure. For
the other loop diuretics, bumetanide, and torsemide. Inexample, in study A (baseline GFR 25 to 55 mL/min/
ADPKD patients, diuretic therapy may promote cyst1.73 m2), the achieved systolic blood pressure adjusted
growth [54] and is associated with more rapid progres-for the 11 relevant covariates of renal disease progression
sion, compared with ACE I therapy (abstract; Ecderaccounted for 9.5% of the variance in GFR decline, while
et al, Am Soc of Nephrol 10:415, 1999). Thus, avoid di-similarly adjusted achieved diastolic blood pressure ac-
uretic therapy and emphasize NaCl restriction in ADPKDcounted for only 2% of the variance in GFR decline [50].
patients.The low blood pressure goal did not significantly slow
If the blood pressure goal is not being met with thisGFR decline in those with proteinuria ,1.0 g/24 hours.
regimen, we recommend that the patient’s blood pres-Nevertheless, it significantly slowed the increase in pro-
sure-measuring technique and equipment should beteinuria over time that typically occurs in progressive renal
checked again for accuracy, and their drug and dietarydisease. This phenomenon is illustrated in Figure 3. Thus,
compliance be assessed. To estimate dietary salt intakeachieving the low blood pressure goal delays the onset
accurately, 24-hour urine creatinine and sodium excre-of major proteinuria and therefore can be regarded as
tion should be measured. If the patient is receivingrenoprotective, even in those with minor proteinuria [5].
NaHCO3 therapy, 24-hour urine chloride should be mea-The low blood pressure goal did not increase cardio-
sured. Note that unless advanced renal insufficiency isvascular or other risks. The low blood pressure goal was
present, NaHCO3 therapy does not usually lead to so-well tolerated in the MDRD Study; however, the MDRD
Study excluded patients with major cardiovascular dis- dium retention [55].
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If the patient is compliant with the measures described zosin-treated ALLHAT patients may have been the re-
sult of inadequate diuretic therapy.previously in this article and blood pressure still is not
at goal, we recommend using triple antihypertensive If triple therapy does not achieve the blood pressure
goal, the patient should be re-evaluated for drug andtherapy, rather than increasing ACE I and diuretic ther-
apy to high levels (discussed later in this article; see dietary compliance. If that evaluation is negative, the
patient should be studied by ambulatory blood pressureACE I therapy).
Triple antihypertensive therapy. The sequence listed monitoring (ABPM) to determine whether sustained hy-
pertension is present [61]. If sustained hypertension isis the approximate level of recommendation.
ACE I, diuretic, and nondihydropyridine calcium chan- documented by ABPM, secondary causes of hyperten-
sion should be sought, particularly renal artery stenosis.nel blocker (ND-CCB, diltiazem and verapamil). The
ND-CCBs in current clinical use are diltiazem and vera- If the evaluation for secondary causes of hypertension
is negative, more intensive triple therapy is recom-pamil. The sustained release preparations are recom-
mended starting at 120 to 180 mg daily. Diltiazem has mended. The initial step is usually an increase in diuretic
therapy. A further increase in ACE I therapy is notfewer side effects, but is considerably more expensive.
The combination of an ACE inhibitor and a ND-CCB recommended to achieve the blood pressure goal.
Rather, high-dose ACE I therapy should be reserved foris more antiproteinuric at the same blood pressure level
than either drug taken alone [56–58]. The dihydropyri- those who have achieved their blood pressure goal and
dietary goals (for salt and protein) but have not achieveddine CCBs (D-CCB; for example, nifedipine, amlodi-
pine, felodipine, nicardipine) are not recommended in their proteinuria goal (discussed later in this article).
If more intense triple therapy does not achieve thepatients with renal disease, unless the D-CCBs are re-
quired to achieve blood pressure control. The concern blood pressure goal, quadruple antihypertensive therapy
is recommended.is that the D-CCBs are not antiproteinuric and may actu-
ally worsen proteinuria, unless strict blood pressure con- Quadruple antihypertensive therapy. The sequence
listed is the approximate level of recommendation.trol is achieved (for example, systolic blood pressure
#110 mm Hg) [59]. If blood pressure control is not ACE I, diuretic, b-blocker, and dihydropyridine cal-
cium channel blocker (D-CCB). This combination is usu-achieved with D-CCB, proteinuria may worsen, and faster
progression of renal disease may occur [12]. ally highly effective in controlling blood pressure. The
D-CCBs are more effective antihypertensive agents thanACE I, diuretic, clonidine. This combination is recom-
mended for individuals receiving insulin (clonidine does the ND-CCBs, but may blunt the renal protection pro-
vided by ACE I therapy [56]. Thus, D-CCBs are recom-not importantly affect glucoregulation) and for those
who may have difficulty with b-blocker therapy (bron- mended only if essential to achieving the blood pressure
goal.chospasm, cardiac conduction). Clonidine tablets are in-
expensive but must be taken at least twice daily. The ACE I, diuretic, b-blocker, and minoxidil. Minoxidil
may be unacceptable in women because it causes gener-clonidine patch is convenient but more expensive.
ACE I, diuretic, b-blocker. This combination is appro- alized hair growth. Minoxidil may worsen proteinuria,
similar to D-CCB. Thus, minoxidil is recommended onlypriate for patients with coronary artery disease. b-Block-
ers can slow recovery from insulin-induced hypoglycemia if needed to achieve the blood pressure goal.
ACE I, diuretic, b-blocker, and a-1 blocker. The addi-but are not contraindicated in diabetes if needed for
blood pressure control. In patients prone to diabetes, tion of a D-CCB or minoxidil will increase the effective-
ness of this combination.b-blocker therapy appears to increase (by 28%) the risk
of developing diabetes [60]. This should be taken into ACE I, diuretic, b-blocker, and clonidine. The combi-
nation of a b-blocker and clonidine can induce bradycar-account when selecting antihypertensive therapies.
ACE I, diuretic, a-1 blocker. This combination is gen- dia but usually is well tolerated. The addition of a D-CCB
or minoxidil will increase the effectiveness of this combi-erally well tolerated and effective. The a-1 blockers ame-
liorate the symptoms of prostatism. The ALLHAT study nation.
If the blood pressure goal is not achieved with quadru-recently discontinued the arm that compared the a-1
blocker doxazocin 1 to 8 mg daily to chlorthalidone 25 mg ple therapy, we recommend that the issues of compliance
and secondary hypertension be revisited.daily as monotherapy to control hypertension. They
found a 25% greater incidence of hospitalization for
2. ACE I therapy (Level 1)congestive heart failure in those randomized to doxa-
zocin (National Institutes of Health Web site). However, There is now compelling evidence based on prospective,
randomized, and controlled clinical trials that ACE I isthe African American Study of Kidney Disease and Hy-
pertension (AASK) External Monitoring Committee de- renoprotective, independent of its antihypertensive ef-
fects, in both diabetic and nondiabetic nephropathies [1].termined to continue to use doxazosin in combination
therapy. The congestive heart failure seen in the doxa- In diabetic nephropathy, ACE I renoprotection is seen
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in both the early nephropathy (microalbuminuria) of in the Ramipril Efficacy in Nephropathy (REIN) trial,
there was no difference in blood pressure control be-both type 1 and type 2 diabetes and in the overt nephrop-
athy of type 1 diabetes [1]. Evidence for renoprotection tween the ramipril group and the placebo group [4].
Furthermore, in the meta-analysis of the randomizedby ACE I in overt nephropathy of type 2 diabetes is less
clear [1]. However, ACE I is believed to be renoprotec- trials of ACE I therapy in nondiabetic renal disease, the
mean difference in systolic blood pressure between thetive in these patients. Indeed, we have observed numer-
ous instances of reversal of nephrotic syndrome and sta- ACE inhibitor groups and the control groups was only
24 mm Hg [3]. Thus, the renoprotection provided bybilization of renal function in type 2 diabetes during
ACE I therapy (unpublished observations). ACE I probably relates mainly to its effects to reduce
proteinuria and to attenuate other actions of angioten-Evidence for ACE I renoprotection, independent of
blood pressure control, has been shown only for overt sin II, as discussed previously in this article.
Because ACE I has only a modest effect to controlnephropathy of type 1 diabetes [1]. Nevertheless, it is
believed that ACE I is renoprotective independent of hypertension, it should not be used as the principal agent
to achieve the blood pressure goal. That is, if the bloodblood pressure control in other forms of diabetic ne-
phropathy [62, 63]. pressure goal is not achieved with moderate dose ACE I
and diuretic therapy, we recommend triple antihyperten-The success of ACE I in forestalling the onset of overt
proteinuria in diabetic patients with microalbuminuria sive therapy, as discussed previously in this article. ACE I
should be used to achieve the proteinuria goal (24-hourhas given rise to the question of whether ACE I should
be given to diabetics without nephropathy. This seems urine protein ,1 g). The rationale for the proteinuria
goal is that in the MDRD Study, the non-ADPKD pa-to be a prudent strategy given the results of the Heart
Outcomes Prevention Evaluation (HOPE) trial showing tients with proteinuria ,1 g/24 hours had the slowest rates
of GFR decline [2]. Furthermore, the long-term follow-that there are broad health benefits from chronic ACE I
therapy and no identifiable health risks [64]. up of diabetic and nondiabetic nephropathy patients in-
dicates that those who achieve the proteinuria goal gen-In nondiabetic nephropathy, ACE I has been shown
to be renoprotective, independent of its effect to control erally have relatively stable renal function [68, 69].
Presently, it is not clear whether increasing the ACE Iblood pressure, but only in patients with nephrotic-range
proteinuria [4]. Nevertheless, adjusting for the effects of dose to high levels (for example, 4 to 8 times the recom-
mended starting dose) increases its antiproteinuric ef-blood pressure control on GFR decline provides evi-
dence that ACE I is also renoprotective independent of fects and/or the degree of renoprotection. However, this
would be a reasonable course of action in patients whoseblood pressure control in nephropathies with lesser lev-
els of proteinuria (1 to 3 g) [65, 66]. nephrotic-range proteinuria persists despite achieving
their blood pressure and dietary goals, while receivingThe renoprotection provided by ACE I can be endur-
ing. In diabetic nephropathy [67, 68] and nondiabetic at least moderate dose ACE I therapy. Of note, increas-
ing the lisinopril dose from 8 to 20 mg daily does notnephropathy [69], follow-ups of 5 to 10 years show sus-
tained remission of nephrotic syndrome and stable or increase its antiproteinuric effect [72]; however, high-
dose ACE I therapy may have benefits. The trials ofeven improving renal function in many patients [68, 69].
Renoprotection in humans has been documented us- ACE I therapy in congestive heart failure suggest that
high-dose ACE I therapy is better than low-dose therapying four different ACE I (enalapril, captopril, benazepril,
and ramipril), and renoprotection is generally regarded in prolonging patient survival [73]. Also, the high-dose
ACE I therapy was generally well tolerated.as a class-specific effect of ACE I [70]. However, there
are pharmacologic differences among ACE inhibitors Determinants of the antiproteinuric response to ACE
inhibitors. The ACE genotype may influence progres-that could be biologically significant [5, 71].
The controlled trials show that the amount of ACE I sion of renal disease [74] and the effect of ACE inhibition
to decrease proteinuria and slow progression of renaltherapy needed to achieve renoprotection is modest (for
example, ,3.0 mg ramipril daily, 5 mg enalapril daily, disease [75]. The latter has been suggested by a recent
re-evaluation of the REIN study in light of the patients’10 mg benazepril daily, or 25 mg captopril 3 times daily).
Whether larger doses of ACE I confer additional reno- ACE gene polymorphism. ACE I therapy in those homo-
zygous for the deletion (D) polymorphism showedprotection is unknown [5].
Goal of ACE I therapy. ACE I therapy is used primar- greater reductions in proteinuria and greater slowing of
GFR decline than those homozygous or heterozygousily to provide renoprotection. Evidence that renoprotec-
tion is being provided by the ACE I therapy is shown for the insertion (I) polymorphism [75]. However, in
diabetics with mild renal manifestations, the oppositeby improved blood pressure control and particularly by
decreased proteinuria [4, 66]. However, ACE I drugs association of ACE I therapy with ACE gene polymor-
phism was found [76].are not particularly potent antihypertensive agents in
patients with chronic renal insufficiency. For example, With respect to the renal mode of action of ACE I or
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angiotensin receptor blockers (ARBs), it has been shown ARB therapy. These drugs are antiproteinuric and an-
tihypertensive in a fashion similar to that of ACE I [83].that plasma renin levels do not predict the renal hemody-
namic response to either ACE I or ARB therapy. This ARBs have a favorable side effects profile in that, com-
pared with ACE I, ARBs are less likely to cause cough,suggests that intrarenal production of angiotensin II,
rather than circulating angiotensin II, is the more impor- angiedema, or hyperkalemia [83]. ARBs are renoprotec-
tive in experimental nephropathy [70] and suppress fibro-tant factor in determining the renoprotective effects of
ACE I or ARB therapy [77]. genic and inflammatory mechanisms similar to ACE I
[84]. Whether ARBs are renoprotective in humans isACE I therapy in those with impaired renal func-
tion. ACE I therapy is renoprotective even in those with unknown. However, there are two ongoing controlled
clinical trials in type 2 diabetes that will assess renopro-substantially impaired kidney function (serum creatinine
$2.5 mg/dL) [4, 66, 68, 78, 79]. Thus, impaired kidney tection by losartan and irbesartan, respectively.
In patients who are intolerant of ACE I (hyperka-function is not a contraindication to ACE I therapy;
however, greater caution is advised. lemia, cough, angiedema, hypersensitivity), ARB ther-
apy is recommended. There is no information to guideIf hyperkalemia develops on ACE I therapy, it is im-
portant to determine whether the hyperkalemia occurred therapy for renoprotective effects of the ARBs; however,
the same general guidelines recommended for ACE Idespite a restricted K1 intake. A 24-hour urine for creati-
nine and potassium best assesses this question. Our expe- therapy may be appropriate for ARB therapy (discussed
previously in this article).rience suggests that if the 24-hour urine for K1 exceeds
50 mEq/24 hours, a reduction in potassium intake should Combination of ACE inhibitor and ARB therapy. Com-
bining these agents has theoretical advantages becauseprevent serious hyperkalemia. However, if the hyperka-
lemia occurred when a 24-hour urine for K1 was less ACE I therapy alone or ARB therapy alone has thera-
peutic loopholes. For ACE I therapy, one loophole isthan 40 mEq/24 hours, it is unlikely that hyperkalemia
can be avoided by dietary measures alone. In that circum- that a substantial portion of the angiotensin II generated
is formed by chymase, which is not inhibited by ACE Istance, an increase in diuretic therapy (if the blood pres-
sure is above goal) or sodium bicarbonate therapy (if therapy [85]. ARB therapy does not suffer from this
loophole because ARBs directly block the angiotensin IIplasma bicarbonate is less than normal) may control the
hyperkalemia. If the hyperkalemia persists despite these type 1 (AT1) receptor. On the other hand, ARBs do not
inhibit the degradation of bradykinin (as do ACE Is)measures, it is best to stop the ACE I. ARB therapy
should then be considered because of its lesser tendency and bradykinin may have an important antihypertensive
effect [85]. Also, ARBs do not significantly suppressto raise serum K1 (discussed later in this article).
Usually serum creatinine increases slightly with ACE I aldosterone production, whereas ACE I drugs do sup-
press it [72] (abstract; Bakris, J Am Soc Nephrol 10:68A,therapy (for example, increases of 0.2 mg/dL for patients
with serum creatinine near 2 mg/dL) [66]. If it is a stable 1999). If aldosterone induces tissue fibrosis [24], thera-
pies such as ACE I that suppress aldosterone would haveincrease in serum creatinine, there is no need to discon-
tinue the ACE I therapy. a therapeutic advantage. Combined ACE I and ARB
therapy may make ARB therapy more efficient becauseInteraction of ACE I therapy with other interventions
that reduce proteinuria. The addition of ACE I therapy less Ang II formation (by ACE I) allows the ARB to
compete better for the AT1 receptor [85].to a low protein diet appears to increase the effect of
these therapies to reduce proteinuria further [80] and In a small study involving IgA nephritis patients, the
combination ACE I/ARB therapy was more effective inslow GFR decline [81]. Thus, the combination of ACE I
therapy and dietary protein restriction can be recom- reducing proteinuria than either therapy alone, despite
similar blood pressure levels [86]. Several clinical trialsmended.
The addition of indomethacin to ACE I therapy or are currently evaluating combination ACE I/ARB ther-
apy in heart disease and in renal disease, respectively.ARB therapy also enhances their antiproteinuric effects
[82]. However, we do not recommend chronic NSAID
3. Control blood glucose in diabetics (Level 1)therapy to reduced proteinuria because of its nephrotox-
icity (discussed both previously and later in this article). For type 1 diabetics, the Hgb A1C goal should be within
two percentage points of the upper limits of normal forAlso, our experience using NSAIDs with ACE I as an
antiproteinuric therapy has generally been disappointing the particular Hgb A1C assay [87, 88].
For type 2 diabetics, the goal is a normal Hgb A1C.in those with severe proteinuria—the patients who would
benefit most from a reduction in proteinuria. In those This recommendation is based on the two major inter-
vention trials in type 2 diabetes, one involving insulinwith minor proteinuria, the benefit of a small further
reduction in proteinuria by the addition of indomethacin therapy [89], the other involving oral hypoglycemic agents
and insulin [90]. In each of these studies, normalizationto ACE I or ARB therapy [82] might be offset by NSAID
nephrotoxicity. of the Hgb A1C was achieved for prolonged periods
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in many of the study patients. In type 2 diabetes, oral which is a strong risk factor for renal disease progres-
sion [50].hypoglycemic agents that control blood glucose at lower
In diabetic nephropathy, the GFR decline is alsoblood insulin levels such as metformin, rosiglitazone, or
slowed by the low protein diet. Indeed, this effect isacarbose have theoretical advantages over sulfonylureas,
greater in diabetic than nondiabetic nephropathy [94].which control blood glucose but increase endogenous
Also, the low protein diet may delay the onset of microal-insulin levels [91]. High endogenous insulin levels are a
buminuria and slow its progression in type I diabetes [99].strong risk factor for adverse cardiovascular outcomes.
Salt (NaCl) intake (Level 2). The NaCl goal of 80 toThus, measures that control blood glucose at lower insu-
120 mmol/day is arbitrary as a renoprotective measure.lin levels may reduce cardiovascular risk. This may also
Its rationale is based on JNC-6 recommendations forslow the development of glomerulosclerosis (discussed
control of blood pressure [61] and the studies showinglater in this article). Of interest is the recent report that
that a high salt diet can completely override the effectthe thiazolidinedione compounds (for example, Avan-
of ACE I or ND-CCB to reduce proteinuria [32, 33]. Adia, Actos) are renoprotective, independent of their insu-
diet containing 80 to 120 mmol NaCl daily can be madelin-sensitivity effects [92].
more palatable if no salt is used in food preparation but
a small amount of salt is added to the surface of the food4. Dietary measures
as it is eaten [55]. For example, a 2 g sodium dietProtein intake (Level 1). Based on the meta-analyses
(88 mmol NaCl) is prescribed. In addition, the patientand secondary analyses of the randomized trials, it can
is allotted 20 to 40 mmol NaCl each day as surface salt.be concluded that protein restriction slows progression
This can be given as 1⁄3 teaspoon of NaCl in a salt shakerof renal disease by about 0.5 mL/min/year) [2, 93–95].
(approximately 25 mmol of NaCl) or as one or two four-When patients are instructed in a dietary protein intake
chamber salt packets (1 g, 17 mmol/L NaCl per packet),of 0.6 g/kg ideal body weight/day, the average achieved
the type commonly available in fast food restaurants.dietary protein intake is 0.7 to 0.8 kg/ideal body weight/
Diuretic therapy can be used to restore the antipro-day. This and lower levels of dietary protein intake are
teinuric effects of ACE I when the patient is not compli-associated with slowed renal disease progression [95].
ant with a low salt intake [100]. However, the combina-There are no known risks to a low protein diet. How-
tion of high salt intake and diuretic therapy can lead toever, in patients with heavy proteinuria, we recommend
significant hypokalemia [55], which itself may promotethat for each gram of proteinuria exceeding 3 g/24 hours,
progression of renal disease (discussed previously andprotein intake be increased by 1 g daily [2, 96]. There
later in this article). Dietary salt intake should be moni-
are no known health benefits to a higher protein diet.
tored by a periodic measurement of 24-hour urine creati-
Indeed, a higher protein diet, particularly meat proteins, nine and sodium, as discussed previously in this article.
can raise blood pressure, increase pathogenic blood lip- Fluid intake (Level 2). Analysis of the MDRD study
ids, and promote hypercalciuria in those with normal showed a significant association between high fluid in-
GFR [7]. Thus, recommending the low protein diet ap- take (high mean follow-up 24-hour urine volume and
pears to be a “no-lose” proposition [97]. low mean follow-up UOsm) and more rapid progressionOur experience is that most patients are able to main- of renal disease (abstract; Hebert et al, J Am Soc Nephrol
tain a low protein diet apparently without great effort 11:148A, 2000). The magnitude of the association is rela-
and without ongoing dietary counseling. We periodically tively large: The difference in GFR decline, adjusted for
monitor dietary protein intake by measuring the creati- covariate of renal disease progression, is 1.0 to 1.5 mL/
nine and urea content in a 24-hour urine collection. min/year greater in those in the highest quartile of 24-
The benefit of the low protein diet in the MDRD hour urine volume (.2.85 L) compared with those in
Study occurred in those with GFRs between 12.5 and the lowest quartile of 24-hour urine volume (,2.0 L).
55 mL/min/1.73 m2. Whether it is beneficial to introduce Thus, based on this secondary analysis of the MDRD
the low protein diet at higher levels of GFR is unknown. Study A patients (GFR 25 to 55 mL/min/1.73 m2, median
However, given the diet’s safety and probable efficacy, serum creatinine 1.9 mg/dL), we suggest that in contrast
the low protein diet can be recommended even in early to some current opinions, chronic high fluid intakes
progressive renal disease. should not be generally recommended in patients with
Another reason to recommend the low protein diet chronic renal insufficiency. This advice may be particu-
in progressive renal disease, even in those with little or larly important in ADPKD patients.
no loss of GFR, is that the low protein goal slows the
5. Control blood lipids (Level 1 for general benefit,increase in proteinuria over time [98]. The effect is al-
Level 2 for renal benefit)most identical to that of the low blood pressure goal, as
shown in Figure 3. Thus, the low protein goal slows the Abundant literature suggests that controlling blood
lipids may slow progression of diabetic and nondiabeticprogression from minor proteinuria to major proteinuria,
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renal disease. The randomized clinical trials have been in chronic hemodialysis patients [107]. However, such
therapy is not practical in nonhemodialysis patients.disappointing since only small numbers of patients have
been studied [reviewed in 101]. Nevertheless, the MDRD Vitamin B12 levels must be normal when dosing with
folic acid so that vitamin B12 depletion of the centralStudy showed that low high-density lipoprotein choles-
terol was an independent risk factor for progression of nervous system does not occur. Severe vitamin B12 defi-
ciency can result in dementia or subacute combined de-renal disease [31], and there is similar evidence that high
cholesterol and perhaps high triglyceride levels promote generation. We commonly use folic acid doses of 5 to
10 mg daily.progression of diabetic glomerulosclerosis [reviewed
in 102]. In the ARIC study (cited previously in this article
9. Control hyperinsulinemia (Level 3)in relationship to procoagulants), low high-density lipo-
protein cholesterol and high triglycerides were indepen- Weight reduction in obese patients and exercise de-
crease insulin resistance in patients with elevated C-pep-dent risk factors for a significant increase in serum creati-
nine during follow-up. There is conclusive evidence that tide levels. Thus, these therapies can be recommended as
a general health measure. In addition, hyperinsulinemiacontrolling blood lipids protects against atherosclerosis
[103]. Thus, it is advisable to encourage blood lipid con- may promote progression of glomerular sclerosis, as dis-
cussed previously in this article. Whether more aggres-trol in patients with progressive renal disease.
The suggested goals for blood lipid control are arbi- sive measures to reduce insulin resistance, such as therapy
with rosiglitazone, or metformin, should be recommendedtrary. However, given the recent evidence that reducing
low-density lipoprotein cholesterol with statin drugs to in patients with high C-peptide levels, and evidence of
progressive glomerulopathy is not clear. However, these,100 mg/dL (mean 70 mg/dL) is well tolerated and asso-
ciated with control of angina [104] suggests that a similar agents are generally well tolerated and do not provoke
hypoglycemia.goal might be appropriate in patients at risk for progres-
sive renal disease.
10. Correct anemia (Level 2)Of note, 3-hydroxy-3-methylglutaryl coenzyme A
(HMG CoA) reductase inhibitors have anti-inflamma- In a randomized trial that demonstrated slower pro-
gression of renal disease with correction of anemia bytory effects by blocking NF-kB activation, a transcription
factor for inflammatory pathways, including the chemo- erythropoietin therapy, the achieved hematocrit was
32% in the erythropoietin group and 25% in the controlkine MCP-1 [reviewed in 105], which is expressed in
both inflammatory and noninflammatory renal diseases group [45]. Thus, the goal hemoglobin of 11 to 12 g/dL
seems appropriate. This is also the hemoglobin goal for[25]. Thus, inflammatory glomerulopathies might be ben-
efited particularly by this therapy. renal failure patients in the National Kidney Foundation
Dialysis Outcomes Quality Index (DOQI) guidelines.
6. No cigarette smoking (Level 1 for general benefit, The renoprotective effect of anemia correction is greater
Level 2 for renal benefit) in nondiabetics than diabetics and may require initiation
of erythropoietin therapy before the serum creatinineCigarettes are bad for everything, even the kidneys
(discussed previously in this article). exceeds 4.0 mg/dL [45].
11. Use antioxidants (Level 3)7. Avoid NSAID agents (Level 2)
In patients with impaired kidney function and chronic Oxidant stress may induce tissue injury and play a
role in progression of renal disease. Participants includepain, we prescribe analgesic medications that are not
known to have nephrotoxicity: plain aspirin, prolonged- plasma homocysteine, plasma lipoproteins, ferric iron,
and vitamin E deficiency (discussed previously in this arti-release aspirin, acetaminophen, propoxyphene, or tra-
madol. Note that the combinations of acetaminophen cle). Based on an animal model of diabetic nephropathy,
a dose of 200 mg of vitamin C has been recommendedand aspirin or acetaminophen and an NSAID may be
nephrotoxic [reviewed in 106]. in humans [108]. High-dose vitamin C therapy is not
recommended because it might lead to excessive deposi-
8. Control homocysteine level (Level 2 for tion of calcium oxalate in tissues. Vitamin E also miti-
cardiovascular benefit, Level 3 for renal benefit) gates oxygen stress and may be beneficial [109].
The goal is to normalize plasma homocysteine. How-
12. Avoid hypokalemia (Level 1 for general benefit,ever, this is difficult in patients with advanced renal insuf-
Level 3 for renal benefit)ficiency in whom only partial reductions in homocysteine
levels are seen despite high-dose folic acid therapy and In experimental models of renal disease, hypokalemia
induces renal hypertrophy and interstitial fibrosis. In pa-supplementation with vitamins B6 and B12 [107]. Recent
evidence suggests that intravenous therapy with folinic tients with chronic severe hypokalemia, progressive re-
nal failure caused by tubular interstitial disease has beenacid may restore elevated homocysteine levels to normal
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well documented [47]. Chronic hypokalemia may also pro- strategy. We recommend that therapy be started early
mote cyst growth in normal kidneys and ADPKD [54]. and even preemptively because the renoprotective inter-
ventions may be more effective if used before overt pro-
13. Control hyperphosphatemia (Level 1 for general teinuria or GFR reduction is present. During pregnancy
benefit, Level 3 for renal benefit) therapies such as ACE I, ARBs, HMG-CoA reductase
Dietary phosphorus restriction (,800 mg of elemental inhibitors, or low-protein diet should be discontinued.
phosphorus daily) and phosphate binders are recom- ADPKD requires special mention because ACE I
mended to maintain the serum phosphorus level within therapy did not slow ADPKD progression in the AIPRI
the normal range. This may slow progression of renal trial [66], and blood pressure control and low-protein
disease (discussed previously in this article). diet did not influence ADPKD progression in the
MDRD Study [2]. Despite these negative outcomes,
14. Low-dose aspirin therapy (Level 1 for general ACE I therapy, strict blood pressure control, and low-
benefit, Level 3 for renal benefit) protein diet are recommended in ADPKD because stud-
Low-dose aspirin therapy is useful in the primary and ies in the genetic models of PKD show benefit in pre-
secondary prevention of myocardial infarction and stroke venting cyst growth if these interventions are begun early
in males [110], but the benefit is less clear in females. [116]. Furthermore, ACE I therapy has general benefits,
Aspirin therapy may also attenuate the effects of in- which include cardiovascular benefits [64]. In experimen-
creased procoagulants that may promote progression of tal models of PKD, HMG CoA reductase inhibitor slows
renal disease (discussed previously in this article). Aspi- renal cyst growth [116]. Thus, this class of drugs may
rin 81 mg daily (“baby” aspirin or one fourth of an adult also be useful in human ADPKD. Finally, it may be
aspirin) is recommended because it is well tolerated and important to avoid a high fluid intake and diuretics in
has a more selective effect on the coagulation system ADPKD patients, as discussed previously in this article.
compared with higher dose aspirin therapy [111]. Patients with directly treatable forms of nephropathy
Aspirin therapy may not be appropriate in ADPKD such as idiopathic membranous nephropathy or lupus
(may promote cyst hemorrhage) or in those at increased nephritis should also be managed with the multiple risk
risk of a hemorrhagic stroke (poorly controlled hyper-
factor intervention strategy because the proteinuria is
tension, Asians, very low serum cholesterol, or family
nonselective and often is chronic. Thus, measures that
history of intracerebral hemorrhage) [110]. In the older
reduce proteinuria may be adjunctive to the immunosup-population, low-dose aspirin therapy has been reported
pression therapy to induce remission of the nephrop-to cause a small (5 to 10%) increase in serum creatinine,
athy [42].uric acid, and blood urea nitrogen level [112]. Aspirin
Those with congenital solitary kidney or solitary kid-therapy does not attenuate the cardiovascular benefits of
ney that was acquired in childhood should be consideredACE I therapy as was once thought [113]. Combination
for renoprotective therapy. These patients appear to bedipyridamole-aspirin therapy may be even more effec-
at increased risk to develop progressive proteinuria andtive than aspirin therapy alone, as it is in stroke preven-
decline in kidney function [117]. Note that in 27 of thetion [114].
MDRD Study patients, the only renal diagnosis was soli-
tary kidney [50].15. Estrogen replacement therapy (Level 2 for general
benefit, Level 3 for renal benefit)
There are multiple theoretical reasons why estrogen RENAL CONDITIONS FOR WHICH
and androgen effects may explain the slower progression RENOPROTECTIVE THERAPIES USUALLY
of renal disease in women than men. However, estrogen ARE NOT INDICATED
therapy may promote sodium retention, worsen hyper-
Some patients with nephropathy are at little or notension, and increase production of pathogenic plasma
increased risk for progressive renal disease. In these pa-lipids [115]. These should be corrected if estrogen re-
tients, renoprotective strategies are not generally recom-placement therapy is used. In men with renal disease, it
mended. These include the following:may be prudent to avoid androgen therapy.
Steroid-responsive minimal change disease (MCD).
However, if proteinuria should become persistent and
RENAL CONDITIONS FOR WHICH steroid resistant, the renoprotective strategies are recom-
RENOPROTECTIVE THERAPY IS mended.
USUALLY INDICATED A solitary kidney that is normal and acquired in adult-
hood, for example, kidney donor. Although kidney do-Any patient with a chronic nephropathy (diabetic,
nors apparently are not at increased risk for progressivenondiabetic, or polycystic) who is at risk for progression
is a candidate for the multiple risk factor intervention renal insufficiency [42], periodic monitoring for hyper-
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tension and abnormal proteinuria or serum creatinine months of the blood pressure and diet intervention, sub-
sequent GFR decline was slowed by about 1 mL/min/levels is recommended.
Hereditary nephritis in the adult whose only renal mani- year [50]. The MDRD Study also suggests that avoidance
of excessive fluid intake could slow progression of renalfestation is microscopic hematuria and who is normoten-
sive. Our experience suggests that this condition does disease by as much as 1 to 1.5 mL/min/year, as discussed
previously in this article. The other recommended mea-not progress. Nevertheless, periodic monitoring is rec-
ommended. sures to slow progression of renal disease (Table 1) may
add further to renoprotection. Indeed, there are no aThin glomerular basement membrane (GBM) disease
in the adult whose only renal manifestation is microscopic priori grounds to suggest that the recommended reno-
protective therapies are antagonistic to one another.hematuria and who is normotensive. Only rarely do these
Although it is likely that the multiple-risk-factor inter-patients develop proteinuria and impaired kidney func-
vention is beneficial, it would be highly desirable to knowtion [118]. Thus, renoprotective interventions are not
how much benefit is achieved. To do that would requirerecommended but periodic monitoring is appropriate.
a prospective trial in which patients are randomized toElderly patients with idiopathic and moderately ele-
usual care or to the multiple-risk-factor intervention. Asvated serum creatinine levels (1.4 to 2.0 mg/dL) and minor
we have previously suggested, such a study would beproteinuria (,1 g/24 hours) whose renal parameters have
more informative and efficient than a series of clinicalbeen stable for at least one year. These patients usually
trials in which the mechanisms of progression are studieddie of nonrenal causes. Thus, renoprotective strategies
singly or only a few at a time [6].probably are more of a nuisance than a benefit in these
If such a study were undertaken, it would be similarpatients.
to the MR FIT study [120]. It seems unlikely, however,Renal conditions that cause acute renal failure but com-
that such a study will be undertaken in the near future.plete or nearly complete recovery of kidney function can
In the meanwhile, nephrologists must make prudent de-be expected. These conditions include acute postinfec-
cisions regarding our patients using evidence that maytious glomerulonephritis (GN), the GN of chronic infec-
not be conclusive. We suggest that the multiple-risk-tion (for example, endocarditis), obstructive uropathy,
factor intervention that is proposed in this article is aacute tubular necrosis from toxins, or ischemia. If the
plausible and prudent approach to the formidable prob-serum creatinine level does not return to normal or if
lem of progression of renal diseases for which no specificabnormal proteinuria persists, the multiple-risk-factor
therapy is available.intervention strategies are recommended.
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